Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries

European Journal of Pharmacology

Volumn 489, Issue 1-2, 2004, Pages 93-100

  Birk, Steffen ^a   Edvinsson, Lars ^a   Olesen, Jes ^a   Kruuse, Christina ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cerebral vasospasm; Cilostazol; Endothelium; Phosphodiesterase inhibitor; Subarachnoid haemorrhage

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; CILOSTAMIDE; CILOSTAZOL; CYCLIC AMP; CYCLIC GMP; FORSKOLIN; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; BRAIN ARTERY; BRAIN VASOSPASM; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DRUG POTENCY; ENZYME ASSAY; GUINEA PIG; HUMAN; HUMAN TISSUE; HYDROLYSIS; MALE; NONHUMAN; PRIORITY JOURNAL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; CEREBRAL ARTERIES; CYCLIC AMP; CYCLIC GMP; ENDOTHELIUM, VASCULAR; GUINEA PIGS; HUMANS; MALE; MILRINONE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; SIGNAL TRANSDUCTION; VASODILATOR AGENTS;

EID: 1942484380     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.02.038     Document Type: Article

References (37)

1. Arakawa Y., Kikuta K., Hojo M., Goto Y., Ishii A., Yamagata S. Milrinone for the treatment of cerebral vasospasm after subarachnoid hemorrhage: report of seven cases. Neurosurgery. 48:2001;723-730.
2. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75:1995;725-748.
3. Bramer S.L., Forbes W.P., Mallikaarjun S. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin. Pharmacokinet. 37:1999;1-11.
4. Cosentino F., Rubattu S., Savoia C., Venturelli V., Pagannonne E., Volpe M. Endothelial dysfunction and stroke. J. Cardiovasc. Pharmacol. 38(Suppl. 2):2001;S75-S78.
5. Delpy E., Coste H., Gouville A.C. Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3. Br. J. Pharmacol. 119:1996;471-478.
6. Eckly A.E., Lugnier C. Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Br. J. Pharmacol. 113:1994;445-450.
7. Furchgott R.F., Vanhoutte P.M. Endothelium-derived relaxing and contracting factors. FASEB J. 3:1989;2007-2018.
8. Gotoh F., Tohgi H., Hirai S., Terashi A., Fukuuchi Y., Otomo E., Shinohara Y., Itho E., Matsuda T., Sawada T., Yamaguchi T., Nishimaru K., Ohashi Y. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J. Stroke Cerebrovasc. Dis. 9:2000;147-157.
9. Inoha S., Inamura T., Ikezaki K., Nakamizo A., Amano T., Fukui M. Type V phosphodiesterase expression in cerebral arteries with vasospasm after subarachnoid hemorrhage in a canine model. Neurol. Res. 24:2002;607-612.
10. Jang E.K., Davidson M.M., Crankshaw D., Haslam R.J. Synergistic inhibitory effects of atriopeptin II and isoproterenol on contraction of rat aortic smooth muscle: roles of cGMP and cAMP. Eur. J. Pharmacol. 250:1993;477-481.
11. Kauffman R.F., Schenck K.W., Utterback B.G., Crowe V.G., Cohen M.L. In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides. J. Pharmacol. Exp. Ther. 242:1987;864-872.
12. Komas N., Lugnier C., Stoclet J.C. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br. J. Pharmacol. 104:1991;495-503.
13. Kruuse C., Rybalkin S.D., Khurana T.S., Jansen-Olesen I., Olesen J., Edvinsson L. The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation. Eur. J. Pharmacol. 420:2001;55-65.
14. Lincoln T.M. Effects of nitroprusside and 8-bromo-cyclic GMP on the contractile activity of the rat aorta. J. Pharmacol. Exp. Ther. 224:1983;100-107.
15. Lindgren S.H., Andersson T.L., Vinge E., Andersson K.E. Effects of isozyme-selective phosphodiesterase inhibitors on rat aorta and human platelets: smooth muscle tone, platelet aggregation and cAMP levels. Acta Physiol. Scand. 140:1990;209-219.
16. Lindgren S., Rascon A., Andersson K.E., Manganiello V., Degerman E. Selective inhibition of cGMP-inhibited and cGMP-noninhibited cyclic nucleotide phosphodiesterases and relaxation of rat aorta. Biochem. Pharmacol. 42:1991;545-552.
17. Liu Y., Shakur Y., Yoshitake M., Kambayashi J.J. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc. Drug Rev. 19:2001;369-386.
18. Lugnier C., Komas N. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur. Heart J. 14(Suppl. I):1993;141-148.
19. Maurice D.H., Crankshaw D., Haslam R.J. Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle. Eur. J. Pharmacol. 192:1991;235-242.
20. Mulvany M.J., Halpern W. Mechanical properties of vascular smooth muscle cells in situ. Nature. 260:1976;617-619.
21. Nakamura T., Houchi H., Minami A., Sakamoto S., Tsuchiya K., Niwa Y., Minakuchi K., Nakaya Y. Endothelium-dependent relaxation by cilostazol, a phosphodiesterase III inhibitor, on rat thoracic aorta. Life Sci. 69:2001;1709-1715.
22. Pauvert O., Salvail D., Rousseau E., Lugnier C., Marthan R., Savineau J.P. Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery. Biochem. Pharmacol. 63:2002;1763-1772.
23. Polson J.B., Strada S.J. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. 36:1996;403-427.
24. Rabe K.F., Tenor H., Dent G., Schudt C., Nakashima M., Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am. J. Physiol. 266:1994;L536-L543.
25. Rascon A., Lindgren S., Stavenow L., Belfrage P., Andersson K.E., Manganiello V.C., Degerman E. Purification and properties of the cGMP-inhibited cAMP phosphodiesterase from bovine aortic smooth muscle. Biochim. Biophys. Acta. 1134:1992;149-156.
26. Schini V., Schoeffter P., Miller R.C. Effect of endothelium on basal and on stimulated accumulation and efflux of cyclic GMP in rat isolated aorta. Br. J. Pharmacol. 97:1989;853-865.
27. Schoeffter P., Lugnier C., Demesy-Waeldele F., Stoclet J.C. Role of cyclic AMP- and cyclic GMP-phosphodiesterases in the control of cyclic nucleotide levels and smooth muscle tone in rat isolated aorta, a study with selective inhibitors. Biochem. Pharmacol. 36:1987;3965-3972.
28. Silver P.J., Lepore R.E., O'Connor B., Lemp B.M., Hamel L.T., Bentley R.G., Harris A.L. Inhibition of the low Km cyclic AMP phosphodiesterase and activation of the cyclic AMP system in vascular smooth muscle by milrinone. J. Pharmacol. Exp. Ther. 247:1988;34-42.
29. Sobey C.G. Cerebrovascular dysfunction after subarachnoid haemorrhage: novel mechanisms and directions for therapy. Clin. Exp. Pharmacol. Physiol. 28:2001;926-929.
30. Sorkin E.M., Markham A. Cilostazol. Drugs Aging. 14:1999;63-71.
31. Stoclet J.-C., Keravis T., Komas N., Lugnier C. Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases. Expert Opin. Investig. Drugs. 4:1995;1081-1100.
32. Sudo T., Tachibana K., Toga K., Tochizawa S., Inoue Y., Kimura Y., Hidaka H. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem. Pharmacol. 59:2000;347-356.
33. Suzuki Y., Huang M., Lederis K., Rorstad O.P. The role of adenylate cyclase in relaxation of brain arteries: studies with forskolin. Brain Res. 457:1988;241-245.
34. Tanaka T., Ishikawa T., Hagiwara M., Onoda K., Itoh H., Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology. 36:1988;313-320.
35. Toyoshima H., Nasa Y., Hashizume Y., Koseki Y., Isayama Y., Kohsaka Y., Yamada T., Takeo S. Modulation of cAMP-mediated vasorelaxation by endothelial nitric oxide and basal cGMP in vascular smooth muscle. J. Cardiovasc. Pharmacol. 32:1998;543-551.
36. Vegesna R.V., Diamond J. Effects of prostaglandin E1, isoproterenol and forskolin on cyclic AMP levels and tension in rabbit aortic rings. Life Sci. 39:1986;303-311.
37. Willette R.N., Shiloh A.O., Sauermelch C.F., Sulpizio A., Michell M.P., Cieslinski L.B., Torphy T.J., Ohlstein E.H. Identification, characterization, and functional role of phosphodiesterase type IV in cerebral vessels: effects of selective phosphodiesterase inhibitors. J. Cereb. Blood Flow Metab. 17:1997;210-219.